Immunity Enhancement in Immunocompromised Gastrointestinal Cancer Patients with Allogeneic Umbilical Cord Blood Mononuclear Cell Transfusion

Table 2

Patients’ status during follow-up.

Patients’ status	UCMC (47 patients)	Control (46 patients)
CR	10.6% (5/47)	13.0% (6/46)
PR	14.9% (7/47)	15.2% (7/46)
SD	44.7% (21/47)	21.7% (10/46)
PD	19.1% (9/47)	41.3% (19/46)
Died	10.6% (5/47)	8.7% (4/46)

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. .